Develops an antibody treatment for Graves’ disease and thyroid eye disease for patients with autoimmune thyroid diseases.
10-K for FY2025, filed Feb 27, 2026
The company receives royalty payments from LEO Pharma when LEO Pharma sells Finacea foam.
10-K for FY2025, filed Feb 27, 2026The Company is entitled to royalty payments with respect to sales of Finacea foam. The Company previously licensed the rights to Finacea…View ↗
$570K
10-K for FY2025, filed Feb 27, 2026
$570K ↗
The company licensed Finacea foam rights to LEO Pharma, which pays royalties when it sells the product.
10-K for FY2025, filed Feb 27, 2026The Company is entitled to royalty payments with respect to sales of Finacea foam. The Company previously licensed the rights to Finacea…View ↗
No. It lost $26.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 13, 2026
−$9.7MView ↗
8-K, filed Jul 28, 2026
Dosing commenced in Phase 2a/2b GD trial following FDA Fast Track Designation, with Phase 2a data expected in 2H 2027View ↗
Shrinking. Revenue fell 39% in 4 years, from $931K in FY2021 to $570K in FY2025, about 12% a year.
Pipeline focus
The older report centers on a topical pan-BET inhibitor and describes an oral selective BET inhibitor in preclinical development. The later report says the topical vitiligo trial ended and shifts the oral program from psoriasis toward other immune-mediated diseases.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Feb 27, 2026
Competes with AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson, UCB, LEO Pharma, Janssen Pharmaceuticals, Roche, Eli Lilly, Pfizer, Novartis, Bausch Health, Sun Pharmaceutical Industries, Takeda Pharmaceutical, and Ventyx Biosciences
10-K for FY2025, filed Feb 27, 2026We are currently developing VYN202 for the treatment of various immune-mediated conditions, which include indications in highly competitive…View ↗
Loading...